PL296382A1 - Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system - Google Patents
Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering systemInfo
- Publication number
- PL296382A1 PL296382A1 PL29638291A PL29638291A PL296382A1 PL 296382 A1 PL296382 A1 PL 296382A1 PL 29638291 A PL29638291 A PL 29638291A PL 29638291 A PL29638291 A PL 29638291A PL 296382 A1 PL296382 A1 PL 296382A1
- Authority
- PL
- Poland
- Prior art keywords
- membrane
- weight
- phospholipid
- cell
- detergent
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000000823 artificial membrane Substances 0.000 title 1
- 239000011324 bead Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 239000012528 membrane Substances 0.000 abstract 4
- 239000003599 detergent Substances 0.000 abstract 3
- 150000003904 phospholipids Chemical class 0.000 abstract 3
- 101710154606 Hemagglutinin Proteins 0.000 abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
- 101710176177 Protein A56 Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000000185 hemagglutinin Substances 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 239000004971 Cross linker Substances 0.000 abstract 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004793 Polystyrene Substances 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 229920002223 polystyrene Polymers 0.000 abstract 1
- -1 sulfosuccinimidyl Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Feedback Control In General (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP91101414A EP0497997B1 (en) | 1991-02-02 | 1991-02-02 | Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems |
| PCT/EP1992/000089 WO1992013525A1 (en) | 1991-02-02 | 1992-01-17 | Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL296382A1 true PL296382A1 (en) | 1993-11-02 |
Family
ID=8206362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL29638291A PL296382A1 (en) | 1991-02-02 | 1991-01-17 | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
| PL92296382A PL170169B1 (en) | 1991-02-02 | 1992-01-17 | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL92296382A PL170169B1 (en) | 1991-02-02 | 1992-01-17 | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6040167A (pl) |
| EP (1) | EP0497997B1 (pl) |
| JP (1) | JP3404037B2 (pl) |
| KR (1) | KR100205693B1 (pl) |
| AT (1) | ATE125154T1 (pl) |
| AU (1) | AU657730B2 (pl) |
| BG (1) | BG61215B1 (pl) |
| BR (1) | BR9204116A (pl) |
| CA (1) | CA2079685C (pl) |
| DE (1) | DE69111414T2 (pl) |
| DK (1) | DK0497997T3 (pl) |
| ES (1) | ES2077086T3 (pl) |
| FI (1) | FI109969B (pl) |
| GE (1) | GEP20002229B (pl) |
| GR (1) | GR3017490T3 (pl) |
| HK (1) | HK56696A (pl) |
| HU (1) | HU215533B (pl) |
| NO (1) | NO306194B1 (pl) |
| PL (2) | PL296382A1 (pl) |
| RO (1) | RO114736B1 (pl) |
| RU (1) | RU2125868C1 (pl) |
| WO (1) | WO1992013525A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5603872A (en) * | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
| DK0525132T3 (da) * | 1991-02-14 | 1996-02-05 | Baxter Int | Binding af genkendende stoffer til liposomer |
| US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| WO1995032706A1 (en) * | 1994-05-31 | 1995-12-07 | Inex Pharmaceuticals Corp. | Virosome-mediated intracellular delivery of therapeutic agents |
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| AU6691496A (en) * | 1995-08-01 | 1997-02-26 | Advanced Therapies, Inc. | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
| CZ299809B6 (cs) * | 1996-05-08 | 2008-12-03 | Nika Health Products Limited | Lipidový vácek mající kladne nabitou membránu z lipidové dvojvrstvy pro prenos genetického materiálu a zpusob jeho prípravy |
| EP1141007B1 (en) * | 1998-12-14 | 2013-05-15 | Dendreon Corporation | Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation |
| US7148324B1 (en) | 1998-12-14 | 2006-12-12 | Dendreon Corporation | Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation |
| JP2004513059A (ja) | 1998-12-24 | 2004-04-30 | ユセベ，ソシエテ アノニム | ペプチド産物、方法及び組成物 |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| CZ20021216A3 (cs) * | 1999-10-08 | 2002-10-16 | Nika Health Products Limited | Lipidové váčky obsahující DOSPER |
| JP4112860B2 (ja) * | 1999-12-17 | 2008-07-02 | ショット アクチエンゲゼルシャフト | 乗員の拘束システムの誘導作動式点火カプセルおよび点火カプセル用のテスト回路 |
| US20040028687A1 (en) * | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
| AU2003233981A1 (en) * | 2002-04-29 | 2003-11-17 | Biotesys Gmbh | Transport system in biological systems |
| EP1447080A1 (en) * | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Method for producing virosome-like particles |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| LT3173073T (lt) | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| WO2007048019A2 (en) * | 2005-10-20 | 2007-04-26 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| WO2009016433A2 (en) * | 2006-09-15 | 2009-02-05 | Ottawa Health Research Institute | Oncolytic rhabdovirus |
| EP4647126A3 (en) | 2015-10-16 | 2026-02-11 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3173713D1 (en) * | 1980-09-05 | 1986-03-20 | Frappier Armand Inst | Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane |
| US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
| US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
| IL86650A0 (en) * | 1987-06-30 | 1988-11-30 | Biophor Corp | Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane |
| AU6358890A (en) * | 1989-09-01 | 1991-04-08 | Board Of Regents, The University Of Texas System | Immunoliposomes for transmittal of activating signals to cells |
| AU652778B2 (en) * | 1990-10-15 | 1994-09-08 | Quest International B.V. | Treatment composition |
-
1991
- 1991-01-17 PL PL29638291A patent/PL296382A1/xx unknown
- 1991-02-02 AT AT91101414T patent/ATE125154T1/de not_active IP Right Cessation
- 1991-02-02 DE DE69111414T patent/DE69111414T2/de not_active Expired - Fee Related
- 1991-02-02 EP EP91101414A patent/EP0497997B1/en not_active Expired - Lifetime
- 1991-02-02 ES ES91101414T patent/ES2077086T3/es not_active Expired - Lifetime
- 1991-02-02 DK DK91101414.0T patent/DK0497997T3/da active
-
1992
- 1992-01-17 WO PCT/EP1992/000089 patent/WO1992013525A1/en not_active Ceased
- 1992-01-17 GE GEAP19921215A patent/GEP20002229B/en unknown
- 1992-01-17 RU SU5053247A patent/RU2125868C1/ru not_active IP Right Cessation
- 1992-01-17 AU AU11693/92A patent/AU657730B2/en not_active Ceased
- 1992-01-17 CA CA002079685A patent/CA2079685C/en not_active Expired - Fee Related
- 1992-01-17 RO RO92-01271A patent/RO114736B1/ro unknown
- 1992-01-17 US US07/930,593 patent/US6040167A/en not_active Expired - Fee Related
- 1992-01-17 JP JP50347192A patent/JP3404037B2/ja not_active Expired - Fee Related
- 1992-01-17 HU HU9203141A patent/HU215533B/hu not_active IP Right Cessation
- 1992-01-17 BR BR929204116A patent/BR9204116A/pt not_active Application Discontinuation
- 1992-01-17 PL PL92296382A patent/PL170169B1/pl not_active IP Right Cessation
- 1992-09-24 NO NO923703A patent/NO306194B1/no not_active IP Right Cessation
- 1992-09-29 BG BG96928A patent/BG61215B1/bg unknown
- 1992-10-01 KR KR1019920702402A patent/KR100205693B1/ko not_active Expired - Fee Related
- 1992-10-01 FI FI924418A patent/FI109969B/fi active
-
1995
- 1995-09-21 GR GR950402607T patent/GR3017490T3/el unknown
-
1996
- 1996-03-28 HK HK56696A patent/HK56696A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20002229B (en) | 2000-09-25 |
| JPH05505406A (ja) | 1993-08-12 |
| RO114736B1 (ro) | 1999-07-30 |
| AU657730B2 (en) | 1995-03-23 |
| KR100205693B1 (en) | 1999-07-01 |
| JP3404037B2 (ja) | 2003-05-06 |
| NO306194B1 (no) | 1999-10-04 |
| AU1169392A (en) | 1992-09-07 |
| FI109969B (fi) | 2002-11-15 |
| BG96928A (bg) | 1994-03-24 |
| EP0497997B1 (en) | 1995-07-19 |
| GR3017490T3 (en) | 1995-12-31 |
| HU215533B (hu) | 1999-01-28 |
| CA2079685C (en) | 2001-11-27 |
| FI924418A7 (fi) | 1993-04-03 |
| RU2125868C1 (ru) | 1999-02-10 |
| FI924418A0 (fi) | 1992-10-01 |
| DE69111414D1 (de) | 1995-08-24 |
| PL170169B1 (en) | 1996-10-31 |
| NO923703L (no) | 1992-11-26 |
| HK56696A (en) | 1996-04-12 |
| ATE125154T1 (de) | 1995-08-15 |
| NO923703D0 (no) | 1992-09-24 |
| US6040167A (en) | 2000-03-21 |
| HU9203141D0 (en) | 1992-12-28 |
| HUT66194A (en) | 1994-10-28 |
| BG61215B1 (en) | 1997-03-31 |
| BR9204116A (pt) | 1993-06-08 |
| ES2077086T3 (es) | 1995-11-16 |
| DE69111414T2 (de) | 1996-02-01 |
| CA2079685A1 (en) | 1992-08-03 |
| WO1992013525A1 (en) | 1992-08-20 |
| EP0497997A1 (en) | 1992-08-12 |
| DK0497997T3 (da) | 1995-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL296382A1 (en) | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system | |
| DE69329677T2 (de) | Kovalente polare lipid-peptid-konjugate für biologisches targeting | |
| Mizuguchi et al. | Efficient gene transfer into mammalian cells using fusogenic liposome | |
| US5550289A (en) | N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor | |
| US5366737A (en) | N-[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses therefor | |
| KR100387561B1 (ko) | 활성제제의조절방출을위한다중소포성리포솜의제법 | |
| DE69535519T2 (de) | Auf hefe basierte vehikel zur abgabe | |
| EP0172907B1 (en) | Liposome-gel compositions | |
| US6120794A (en) | Emulsion and micellar formulations for the delivery of biologically active substances to cells | |
| Perrin et al. | Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre-and post-exposure protection studies | |
| WO1985004880A1 (en) | Fused liposome and acid induced method for liposome fusion | |
| US4148876A (en) | Biological preparations | |
| NZ332666A (en) | Cationic virosomes having a positively charged lipid bilayer membrane with an integrated viral fusogenic peptide as genetic transfer systems for use in gene therapy | |
| US5283122A (en) | Fused liposome and acid induced method for liposome fusion | |
| CA1079634A (en) | Antigens bound to exterior surface of microvesicles | |
| Jain et al. | Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism | |
| Van Deenen et al. | Penetration of lipid monolayers by psychoactive drugs | |
| HUT62457A (en) | Process for producing aqueous liposomal suspensions comprising an active ingredient | |
| IL175573A (en) | Pharmaceutical compositions comprising vaccine antigen(s) other than a coding dna and phosphoric ester derivative(s) of phosphatidylcholine and their use for preparing a vaccine adjuvant | |
| Gurari-Rotman et al. | Encapsulation of human fibroblast interferon activity in liposomes | |
| Wood et al. | Transmembrane orientation of lipophilin in phosphatidylcholine vesicles | |
| Jaafari et al. | Targeting of Liposomes to Human Keratinocytes Through Adhesive Peptides from Immunoglobulin Domains in the Presence of IFNM-γ | |
| ATE61222T1 (de) | Aspoxicillin enthaltende medizinalzubereitung, ein verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels. | |
| Gonser et al. | Vaccines and their transfection potency | |
| Philippot et al. | LIPOSOMES as TOOLS in BASIC RESEARCH and |